In sterile aqueous injectables for production animals, the high-HLB castor oil ethoxylate fraction (HLB 13–16) is evaluated as a micellar solubilizer for poorly water-soluble active pharmaceutical ingredients with log P 3–5. The formulation route requires mapping the cloud point of the final aqueous vehicle before terminal steam sterilization is fixed; a 121°C/15 min autoclave cycle can exceed the cloud point of diluted castor oil ethoxylate unless the surfactant is kept within a micellar region and the ionic strength is controlled. At 5–20% w/w high-HLB castor oil ethoxylate, micellar uptake is generally sufficient only for low-dose actives; higher doses may require co-solvent adjustment with propylene glycol or ethanol, which alters micelle size and raises the risk of phase separation during pH adjustment.Production-scale mixing begins with overhead high-shear dispersion at 5,000–12,000 rpm for 10–30 minutes under nitrogen sparging to reduce peroxide formation, followed by high-pressure homogenization at 500–800 bar with heat exchanger outlet temperature not exceeding 40°C. The liquid is filtered through 0.22 µm PVDF or PES membranes; nylon and polysulfone filters may foul through interaction with the ethylene oxide chain. Terminal sterilization at 121°C is acceptable only when stability data demonstrate no increase in peroxide value, no pH drift greater than 0.3 units, and no visual phase separation. The most frequent production failure is phase inversion during pH adjustment below 4.0 or above 8.0 in the presence of salts. Endotoxin control requires a vendor specification consistent with the final dose volume and route; a limit of not more than 1.0 IU/mg is a common reject criterion for injectable-grade material. Residual ethylene oxide and 1,4-dioxane must meet the applicable pharmacopoeial monograph for polyoxyl castor oil or a validated veterinary release specification. Published animal-specific safety data for parenteral castor oil ethoxylate remains limited; target animal safety studies under VICH GL43 are required before use in injectable products.

When the ethoxylate enters a high-shear wet granulation train for veterinary tablet cores

In high-shear granulation using a top-drive impeller at 3–8 m/s tip speed and chopper at 1,500–3,000 rpm, a medium-HLB castor oil ethoxylate (HLB 11–15) is introduced as an aqueous binder solution at 0.5–3.0% w/w of the dry powder mass. The surfactant lowers water surface tension and permits a lower liquid-to-solids ratio, but overwetting appears quickly because the same surface activity spreads granulating liquid over a larger wetted surface. Batch records from high-shear mixers show that a 1.5% w/w castor oil ethoxylate solution can reduce required water by 10–20% compared with a 5% w/w PVP K30 binder solution, while shifting granule size distribution toward a bimodal profile if the spray rate is not reduced.Fluid-bed drying with inlet air at 50–65°C is operational only while the exhaust air stays below the cloud point of the specific ethoxylate fraction. Local overheating above cloud point produces tacky granule surfaces that migrate to the filter bag and reduce airflow. The dried granulate is milled through a 0.8–1.25 mm screen; low-EO fractions should be avoided because they can plasticize under milling heat and cause smearing. Compression on a rotary tablet press at 10–20 kN requires 0.5–1.0% w/w magnesium stearate to manage ejection friction. Dissolution testing under USP <711> with Apparatus 2 at 50 rpm in pH 6.8 phosphate buffer may show narrower release variability than poorly wetted control tablets, but the result depends on active particle size and tablet hardness. Storage above 60% RH is a defined operational boundary: tablets containing more than 2.0% w/w castor oil ethoxylate can pick up from the die wall or soften on the press.

Why capsule fill rheology shifts under 40°C pump-and-fill operations

Capsule filling of veterinary products is carried out with hard gelatin or HPMC shells on rotary plunger and dosing pump machines. Castor oil ethoxylate with HLB 12–14 is used at 10–30% w/w in lipid-based fill matrices composed of medium-chain triglycerides, glycerol monooleate, or propylene glycol monocaprylate. The fill matrix must remain below 800 mPa·s at 40°C to prevent pump cavitation and fill weight drift. Low-EO castor oil ethoxylate fractions with higher viscosity are generally avoided in capsule pump systems. During filling, the product temperature is held at 35–45°C; below 30°C semi-solid lipid systems can solidify or exceed pump torque limits, while above 45°C oxidative decomposition accelerates.Hard gelatin shells are sensitive to water migration from hygroscopic ethoxylates. At 50–60% RH, the fill may pull moisture from the shell and induce brittleness; above 65% RH, the shell softens and may deform on the conveyor. Gelatin cross-linking is a known failure mode when peroxide-generated aldehydes react with amino groups in the shell. A low-peroxide grade castor oil ethoxylate and storage below 25°C delay pellicle formation. HPMC shells show less aldehyde-mediated cross-linking but have lower shell moisture, which changes the moisture equilibrium with the fill. Content uniformity depends on maintaining the active in suspension before encapsulation; an airless mixing vessel with planetary stirrer at 30–50 rpm is common for semi-solid suspensions. Differential scanning calorimetry is used to verify no crystalline precipitation occurs within 24 hours at 25°C. If precipitation occurs, the ethoxylate fraction or co-solvent ratio must be adjusted; published formulation-specific data for veterinary capsule systems is often proprietary and limited.

Medicated feed premix homogeneity limits at 2–5 kg/tonne

In feed premix production, castor oil ethoxylate is applied as a low-dusting wetting agent onto carriers such as corn cob grit, rice hull, calcium carbonate, or wheat middlings. The target inclusion is usually 1.0–3.0% w/w of the premix mass, corresponding to low gram-level exposure per tonne of final feed. The compound binds hydrophobic active particles to the carrier and reduces fine dust. Sieve analysis before and after mixing commonly shows a shift of particles below 150 µm into the 300–1,000 µm range when mixing is performed in a double-shaft paddle mixer for 8–15 minutes at 30–60 rpm.Homogeneity in final feed is checked by assay of composite samples taken from a ribbon mixer; the coefficient of variation should not exceed 5.0% for active pharmaceutical ingredient distribution under Commission Regulation (EU) 2019/4 and EU 2019/6 expectations for medicated feedingstuffs. Overwetting is the main production failure: applying more than 3.0% w/w liquid ethoxylate to corn cob carrier creates agglomerates that do not break down in final feed and cause carryover between batches. For high-dose premixes, the ethoxylate may first be dispersed onto hydrophobic fumed silica at 1:1 to 1:3 ratios to ease handling. Stability is monitored at 25°C and 60% RH for 6–12 months; peroxide value and acid value are retested because oxidative by-products can bind pigments, vitamins, and ionophore actives. Premix operations must comply with Good Manufacturing Practice for veterinary medicinal products and medicated feed; release is governed by the marketing authorization, not only feed hygiene criteria.

Application-specific working limits for castor oil ethoxylate fractions

Dosage form	COE HLB range	Typical loading	Critical process limit	Reference standard or equipment
Injectable aqueous solution	13–16	5–20% w/w	Autoclave cycle 121°C/15 min may cause cloud-point phase separation; filter 0.22 µm	VICH GL43
Tablet wet granulation	11–15	0.5–3.0% w/w	Impeller 3–8 m/s; exhaust below cloud point; storage <60% RH	USP <711>
Capsule liquid fill	12–14	10–30% w/w of fill	Fill viscosity <800 mPa·s at 40°C; storage 25°C	Hard gelatin or HPMC shell
Medicated feed premix	9–12	1.0–3.0% w/w on carrier	Mixer CV ≤5.0%; storage ≤25°C and ≤60% RH	EU 2019/4, EU 2019/6
Oral drench or drinking water stock	12–15	1.0–5.0% w/w	Cloud point >60°C; hard water >250 mg/L requires chelator	VICH stability protocol
Hot melt extrusion granule	11–14	5–15% w/w of melt feed	Barrel 90–130°C; residence 3–5 min; nitrogen vent	Twin screw L/D 40:1

Aqueous oral drench and drinking water stock solutions rely on a medium-to-high HLB castor oil ethoxylate fraction (HLB 12–15) at 1.0–5.0% w/w to dissolve hydrophobic actives before dilution into water. The stock solution is usually formulated at 50–100 times the final drinking water concentration; cloud point must remain above 60°C because farm water lines may be flushed with warm water or exposed to direct sun. Hard water containing magnesium and calcium ions depresses cloud point and can produce turbidity in drinking water lines, so a chelator such as disodium EDTA at 0.1–0.5% w/w is added when water hardness exceeds 250 mg/L as calcium carbonate.Oral drench formulations must remain free of particulate precipitation after 24 hours at 5°C and after freeze-thaw cycles. The high-EO fractions resist phase separation in cold water, but they also increase foaming during mixing. Foam is controlled by vacuum deaeration or sub-surface filling rather than high levels of silicone oil, which can affect dose uniformity and palatability. The final solution is packaged in HDPE bottles with induction-sealed caps; oxidation at the bottle neck is reduced by nitrogen flushing during filling. In-feed water medication through a proportional dosing pump is less forgiving than drench packaging because the stock solution residence time in the pump and tubing can exceed 48 hours; ethoxylate concentration and preservative efficacy must be validated for this dwell time. Published data for specific actives in such systems is often available only in marketing authorization dossiers, and formulation-specific stability programs are required.For water-dispersible oral powders presented in sachets or bottles, low dusting and rapid wetting are the dominant design targets. A high-HLB castor oil ethoxylate (HLB 13–16) is dry-blended at 0.5–2.0% w/w with micronized active and a water-soluble carrier such as lactose monohydrate or sorbitol. The powder is intended to be mixed by the end user with drinking water or milk replacer. Wetting time is measured by sprinkling 5 g of the powder onto 500 mL of water at 25°C without stirring. Complete wetting within 60–120 seconds is typical, but the result depends on carrier particle size and active hydrophobicity.Long-term physical stability is limited by moisture ingress: at RH above 60%, the powder cakes and the ethoxylate may become tacky. Sachets must therefore use a moisture barrier film such as aluminum foil laminate. Content uniformity of such low-dose powders is controlled by geometric dilution and final blending in a double-cone or V-blender for 15–30 minutes. A common production failure is segregation during filling because the surfactant-coated active adheres to coarse carrier particles. This is detected by powder blend uniformity testing or unit-dose content uniformity. A formulation with a high fine fraction below 75 µm may require compact granulation or dry granulation to prevent segregation.

Hot melt extrusion: barrel residence time and peroxide thresholds

Veterinary granule and tablet intermediates processed by hot melt extrusion require the ethoxylate as a melt plasticizer and solubilizer in co-rotating twin-screw equipment. A co-rotating twin-screw extruder with L/D 40:1 and screw diameter 16–27 mm is run at screw speed 100–400 rpm and barrel temperature 90–130°C when processing water-insoluble active compounds with hydroxypropyl methylcellulose acetate succinate, polyvinylpyrrolidone-co-vinyl acetate, or methacrylate polymers. The ethoxylate reduces melt viscosity and permits lower barrel temperatures; torque is monitored as a real-time indicator of melt loading.At 5–15% w/w castor oil ethoxylate in the molten feed, specific mechanical energy decreases, but plasticization is limited by oxidation of the ethylene oxide chain. Peroxide formation is accelerated above 130°C, and vent ports must remain open with nitrogen sweep to remove volatile decomposition products. Residence time in the barrel is controlled to less than 3–5 minutes by screw design and throughput; longer residence time at high barrel temperature increases peroxide value and may form aldehydes that react with amine-containing actives. The extrudate is cooled on a belt to 25–35°C and milled through a 0.5–1.0 mm screen. Milled granules are evaluated by modulated differential scanning calorimetry for amorphous conversion and by X-ray powder diffraction for residual crystallinity. The ethoxylate alone does not guarantee amorphous stability; partial recrystallization may occur within 30 days at 40°C/75% RH if the polymer ratio is too low. This route is unsuitable for moisture-sensitive actives unless a vacuum vent is fitted and the raw material has a defined low peroxide value. Published data for specific veterinary APIs in this configuration is limited; feasibility batches are required before scale-up.